Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Inventory (2022 - 2024)

Amylyx Pharmaceuticals (AMLX) has 3 years of Change in Inventory data on record, last reported at $9.3 million in Q1 2024.

  • For Q1 2024, Change in Inventory fell 30.44% year-over-year to $9.3 million; the TTM value through Dec 2024 reached $9.3 million, down 87.35%, while the annual FY2024 figure was $9.3 million, 87.35% down from the prior year.
  • Change in Inventory reached $9.3 million in Q1 2024 per AMLX's latest filing, down from $26.5 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $26.5 million in Q4 2023 and bottomed at $9.2 million in Q4 2022.
  • Average Change in Inventory over 3 years is $15.3 million, with a median of $13.7 million recorded in 2023.
  • Peak YoY movement for Change in Inventory: skyrocketed 187.65% in 2023, then crashed 30.44% in 2024.
  • A 3-year view of Change in Inventory shows it stood at $9.2 million in 2022, then surged by 187.65% to $26.5 million in 2023, then plummeted by 65.06% to $9.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were $9.3 million in Q1 2024, $26.5 million in Q4 2023, and $14.0 million in Q3 2023.